Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: A randomized controlled trial

BMC Nephrology

Volumn 17, Issue 1, 2016, Pages

  Roberts, Matthew A ^a,b   Huang, Louis ^a,b   Lee, Darren ^a,b   MacGinley, Robert ^a,b   Troster, Stefanie M A ^b   Kent, Annette B ^a,b   Bansal, Sukhvinder S ^c   Macdougall, Iain C ^d   McMahon, Lawrence P ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b EASTERN HEALTH   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Fibroblast growth factor 23; Haemodialysis; Hepcidin; Iron infusion; Randomized controlled trial

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; FIBROBLAST GROWTH FACTOR 23; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR; IRON; IRON SACCHARATE; PHOSPHATE; ANTIANEMIC AGENT; FERRIC ION; FIBROBLAST GROWTH FACTOR; MALTOSE; SACCHARIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; SELF REPORT; SINGLE DRUG DOSE; URINE VOLUME; VERY ELDERLY; ANALOGS AND DERIVATIVES; BLOOD; CHRONIC KIDNEY FAILURE; DRUG EFFECTS; FEMALE; HEMODIALYSIS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED;

ADMINISTRATION, INTRAVENOUS; AGED; FEMALE; FERRIC COMPOUNDS; FIBROBLAST GROWTH FACTORS; GLUCARIC ACID; HEMATINICS; HUMANS; MALE; MALTOSE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84995480815     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-016-0391-7     Document Type: Article

References (25)

1. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370-8.
2. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584-92.
3. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305(23):2432-9.
4. Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens. 2014;23(4):411-9.
5. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci. 2011;108(46):E1146-55.
6. Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013;27(1):41-53.
7. David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, Zumbrennen-Bullough KB, Sun CC, Lin HY, Babitt JL, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2015;89(1):135-46.
8. Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol. 2015;26(6):1238-47.
9. Winkelmayer WC, Mitani AA, Goldstein BA, Brookhart MA, Chertow GM. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med. 2014;174(5):699-707.
10. Schouten BJ, Doogue MP, Soule SG, Hunt PJ. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009;46(Pt 2):167-9.
11. Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009;45(4):814-6.
12. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009;94(7):2332-7.
13. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28(8):1793-803.
14. Hryszko T, Rydzewska-Rosolowska A, Brzosko S, Koc-Zorawska E, Mysliwiec M. Low molecular weight iron dextran increases fibroblast growth factor-23 concentration, together with parathyroid hormone decrease in hemodialyzed patients. Ther Apher Dial. 2012;16(2):146-51.
15. Takeda Y, Komaba H, Goto S, Fujii H, Umezu M, Hasegawa H, Fujimori A, Nishioka M, Nishi S, Fukagawa M. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol. 2011;33(5):421-6.
16. Macginley R, Walker R, Irving M. KHA-CARI Guideline: use of iron in chronic kidney disease patients. Nephrology (Carlton). 2013;18(12):747-9.
17. Smith ER. The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin J Am Soc Nephrol. 2014;9(7):1283-303.
18. Bansal SS, Abbate V, Bomford A, Halket JM, Macdougall IC, Thein SL, Hider RC. Quantitation of hepcidin in serum using ultra-high-pressure liquid chromatography and a linear ion trap mass spectrometer. Rapid Comm Mass Spectrom. 2010;24(9):1251-9.
19. Pechlaner R, Kiechl S, Mayr M, Santer P, Weger S, Haschka D, Bansal SS, Willeit J, Weiss G. Correlates of serum hepcidin levels and its association with cardiovascular disease in an elderly general population. Clin Chem Lab Med. 2016;54(1):151-61.
20. Prats M, Font R, Garcia C, Cabre C, Jariod M, Vea AM. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study. BMC Nephrol. 2013;14:167.
21. Smith ER, Cai MM, McMahon LP, Holt SG. Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab. 2012;97(9):3357-65.
22. Jahn MR, Andreasen HB, Futterer S, Nawroth T, Schunemann V, Kolb U, Hofmeister W, Munoz M, Bock K, Meldal M, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78(3):480-91.
23. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol. 2011;22(10):1913-22.
24. Unver S, Kavlak E, Gumusel HK, Celikbilek F, Esertas K, Muftuoglu T, Kirilmaz A. Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients. Ren Fail. 2015;37(6):951-6.
25. Di Marco GS, Reuter S, Kentrup D, Grabner A, Amaral AP, Fobker M, Stypmann J, Pavenstadt H, Wolf M, Faul C, et al. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant. 2014;29(11):2028-35.